|
US6506798B1
(en)
|
1997-07-01 |
2003-01-14 |
Warner-Lambert Company |
4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
|
|
US6846799B1
(en)
|
1998-08-18 |
2005-01-25 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
US7354894B2
(en)
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
AU2180500A
(en)
*
|
1998-12-15 |
2000-07-03 |
Warner-Lambert Company |
Use of a mek inhibitor for preventing transplant rejection
|
|
AU2203800A
(en)
*
|
1999-01-07 |
2000-07-24 |
Warner-Lambert Company |
Antiviral method using mek inhibitors
|
|
HUP0105092A3
(en)
*
|
1999-01-13 |
2003-12-29 |
Warner Lambert Co |
1-heterocycle substituted diarylamines and medicaments containing them
|
|
EP1144372B1
(en)
|
1999-01-13 |
2005-11-30 |
Warner-Lambert Company Llc |
Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
|
|
CA2348236A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Stephen Douglas Barrett |
4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
|
|
CA2355470C
(en)
|
1999-01-13 |
2008-09-30 |
Warner-Lambert Company |
Benzoheterocycles and their use as mek inhibitors
|
|
CA2349832A1
(en)
|
1999-01-13 |
2000-07-20 |
Warner-Lambert Company |
Benzenesulfonamide derivatives and their use as mek inhibitors
|
|
DE60017109T2
(de)
*
|
1999-04-21 |
2006-01-12 |
Warner-Lambert Co. Llc |
Verfahren zur herstellung von 2-(n-phenylalmino)benzoesäure
|
|
US6686499B1
(en)
|
1999-04-21 |
2004-02-03 |
Warner-Lambert Company |
Method for making 2-(N-phenylamino)benzoic acids
|
|
GB9910577D0
(en)
*
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910579D0
(en)
*
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
JP2003504400A
(ja)
*
|
1999-07-16 |
2003-02-04 |
ワーナー−ランバート・カンパニー |
Ｍｅｋ阻害剤を用いた慢性痛の治療方法
|
|
EP1339702A1
(en)
|
2000-03-15 |
2003-09-03 |
Warner-Lambert Company |
5-amide substituted diarylamines as mek inhibitors
|
|
BR0109188A
(pt)
*
|
2000-03-15 |
2003-03-18 |
Warner Lambert Co |
Diarilaminas 5-amida substituìdas como inibidores de mex
|
|
DE10017480A1
(de)
*
|
2000-04-07 |
2001-10-11 |
Transmit Technologietransfer |
Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
|
|
DZ3401A1
(fr)
*
|
2000-07-19 |
2002-01-24 |
Warner Lambert Co |
Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
|
|
KR20030059115A
(ko)
*
|
2000-08-25 |
2003-07-07 |
워너-램버트 캄파니 엘엘씨 |
Ｎ-아릴-안트라닐산 및 그의 유도체의 제조 방법
|
|
AU8856201A
(en)
|
2000-09-01 |
2002-03-13 |
Andel Inst Van |
Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
|
|
EP1337524A1
(en)
|
2000-11-02 |
2003-08-27 |
AstraZeneca AB |
Substituted quinolines as antitumor agents
|
|
EP1337513A1
(en)
|
2000-11-02 |
2003-08-27 |
AstraZeneca AB |
4-substituted quinolines as antitumor agents
|
|
WO2002076496A1
(en)
*
|
2001-03-22 |
2002-10-03 |
Van Andel Institute |
Anthrax lethal factor inhibits tumor growth and angiogenesis
|
|
IL149462A0
(en)
*
|
2001-05-09 |
2002-11-10 |
Warner Lambert Co |
Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
|
|
EP1467968A1
(en)
*
|
2002-01-23 |
2004-10-20 |
Warner-Lambert Company LLC |
N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
|
|
DOP2003000556A
(es)
|
2002-01-23 |
2003-10-31 |
Warner Lambert Co |
Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
|
|
SG2013013339A
(en)
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
US7235537B2
(en)
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
CA2532067C
(en)
|
2003-07-24 |
2010-12-21 |
Stephen Douglas Barrett |
N-methyle-substituted benzamidazoles
|
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
US8084645B2
(en)
|
2003-09-19 |
2011-12-27 |
Chugai Seiyaku Kabushiki Kaisha |
4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
|
|
WO2005040098A1
(en)
|
2003-10-21 |
2005-05-06 |
Warner-Lambert Company Llc |
Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
|
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
CA2546353A1
(en)
|
2003-11-19 |
2005-06-09 |
Array Biopharma Inc. |
Bicyclic inhibitors of mek and methods of use thereof
|
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
CA2546754A1
(en)
|
2003-11-21 |
2005-06-09 |
Array Biopharma Inc. |
Akt protein kinase inhibitors
|
|
UA89035C2
(ru)
|
2003-12-03 |
2009-12-25 |
Лео Фарма А/С |
Эфиры гидроксамовых кислот и их фармацевтическое применение
|
|
CA2561516A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
MY144232A
(en)
|
2004-07-26 |
2011-08-15 |
Chugai Pharmaceutical Co Ltd |
5-substituted-2-phenylamino benzamides as mek inhibitors
|
|
ATE404556T1
(de)
|
2004-08-17 |
2008-08-15 |
Hoffmann La Roche |
Substituierte hydantoine
|
|
TW200621766A
(en)
*
|
2004-09-17 |
2006-07-01 |
Hoffmann La Roche |
Substituted hydantoins
|
|
MX2007004781A
(es)
|
2004-10-20 |
2007-05-11 |
Applied Research Systems |
Derivados de 3-arilamino piridina.
|
|
WO2006109661A1
(ja)
|
2005-04-06 |
2006-10-19 |
Chugai Seiyaku Kabushiki Kaisha |
２，３，４－トリフルオロ－５－（ヨード又はブロモ）安息香酸の製造方法
|
|
SG177981A1
(en)
|
2005-05-18 |
2012-02-28 |
Array Biopharma Inc |
4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
|
|
HRP20110498T1
(hr)
|
2005-10-07 |
2011-08-31 |
Exelixis |
Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
|
|
US7612212B2
(en)
|
2006-02-22 |
2009-11-03 |
Hoffmann-La Roche Inc. |
Substituted hydantoins
|
|
WO2007132867A1
(ja)
|
2006-05-15 |
2007-11-22 |
Takeda Pharmaceutical Company Limited |
癌の予防及び治療剤
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
US8329701B2
(en)
|
2006-07-06 |
2012-12-11 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as AKT protein kinase inhibitors
|
|
ATE532789T1
(de)
|
2006-07-06 |
2011-11-15 |
Array Biopharma Inc |
Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
|
|
EP2049500B1
(en)
|
2006-07-06 |
2011-09-07 |
Array Biopharma, Inc. |
Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
|
EP1908751A1
(en)
*
|
2006-10-03 |
2008-04-09 |
EOS S.p.A. |
N-hydroxy benzamides with antitumour activity
|
|
WO2008140553A2
(en)
|
2006-10-23 |
2008-11-20 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
WO2008076415A1
(en)
|
2006-12-14 |
2008-06-26 |
Exelixis, Inc. |
Methods of using mek inhibitors
|
|
JPWO2008075741A1
(ja)
*
|
2006-12-20 |
2010-04-15 |
国立大学法人 長崎大学 |
糖尿病治療剤及び予防剤
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
CN101918373B
(zh)
|
2007-07-05 |
2013-06-05 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
CN103396409B
(zh)
|
2007-07-05 |
2015-03-11 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
MX2010001581A
(es)
|
2007-08-16 |
2010-03-15 |
Hoffmann La Roche |
Hidantoinas substituidas.
|
|
US8063085B2
(en)
|
2007-12-20 |
2011-11-22 |
Hoffmann-La Roche Inc. |
Substituted hydantoins
|
|
NZ586346A
(en)
|
2008-01-09 |
2012-02-24 |
Array Biopharma Inc |
Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
US8853216B2
(en)
|
2008-01-09 |
2014-10-07 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
|
|
US8530457B2
(en)
|
2008-05-20 |
2013-09-10 |
Fox Chase Cancer Center |
Method for the treatment of lymphangioleiomyomatosis (LAM)
|
|
UA107183C2
(uk)
|
2008-08-04 |
2014-12-10 |
|
Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
|
|
EP2346827B1
(en)
|
2008-08-27 |
2013-11-13 |
Leo Pharma A/S |
Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
|
|
US8993630B2
(en)
|
2008-11-10 |
2015-03-31 |
Bayer Intellectual Property Gmbh |
Substituted sulphonamido phenoxybenzamides
|
|
EP2370568B1
(en)
|
2008-12-10 |
2017-07-19 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
US20120269803A1
(en)
|
2009-10-21 |
2012-10-25 |
Bayer Intellectual Property Gmbh |
Substituted benzosulphonamides
|
|
EP2491015A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
US20120263714A1
(en)
|
2009-10-21 |
2012-10-18 |
Bayer Intellectual Property Gmbh |
Substituted halophenoxybenzamide derivatives
|
|
EP3028699B1
(en)
|
2010-02-25 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
|
CN103038364A
(zh)
|
2010-03-09 |
2013-04-10 |
达纳－法伯癌症研究所公司 |
诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
|
|
CN103282351A
(zh)
|
2010-10-29 |
2013-09-04 |
拜耳知识产权有限责任公司 |
取代的苯氧基吡啶
|
|
WO2012087965A2
(en)
|
2010-12-22 |
2012-06-28 |
Fate Therapauetics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
|
|
KR102021157B1
(ko)
|
2011-04-01 |
2019-09-11 |
제넨테크, 인크. |
Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
|
|
TR201815685T4
(tr)
|
2011-04-01 |
2018-11-21 |
Genentech Inc |
Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
|
|
ES2597052T3
(es)
|
2011-05-25 |
2017-01-13 |
Université Paris Descartes |
Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal
|
|
CN103204827B
(zh)
|
2012-01-17 |
2014-12-03 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
MA38085B1
(fr)
|
2012-10-12 |
2018-11-30 |
Exelixis Inc |
Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
|
|
EP3043822A1
(en)
|
2013-09-11 |
2016-07-20 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Compositions for preparing cardiomyocytes
|
|
CA2935804A1
(en)
|
2014-01-14 |
2015-07-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
|
|
SG11201606934SA
(en)
|
2014-03-04 |
2016-09-29 |
Fate Therapeutics Inc |
Improved reprogramming methods and cell culture platforms
|
|
US10023879B2
(en)
|
2014-06-04 |
2018-07-17 |
Fate Therapeutics, Inc. |
Minimal volume reprogramming of mononuclear cells
|
|
CN105384754B
(zh)
*
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
AU2015328411C1
(en)
|
2014-10-06 |
2022-03-03 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
AU2016211671B2
(en)
|
2015-01-26 |
2022-05-26 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
SG10202111851YA
(en)
|
2015-10-16 |
2021-12-30 |
Fate Therapeutics Inc |
Platform for the Induction & Maintenance of Ground State Pluripotency
|
|
CA3003152A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
JP6928604B2
(ja)
|
2015-11-04 |
2021-09-01 |
フェイト セラピューティクス，インコーポレイテッド |
万能性細胞のゲノム改変
|
|
EP3405568A4
(en)
|
2016-01-20 |
2019-12-04 |
Fate Therapeutics, Inc. |
COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
|
|
CA3010236A1
(en)
|
2016-01-20 |
2017-07-27 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
US10913728B2
(en)
*
|
2016-07-28 |
2021-02-09 |
The Johns Hopkins University |
O-substituted hydroxamic acids
|
|
WO2018106595A1
(en)
|
2016-12-05 |
2018-06-14 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
CN107556201B
(zh)
*
|
2017-09-08 |
2020-10-27 |
山西智创药研科技有限公司 |
一种制备间氨基苯酚的工艺方法
|
|
MA55143A
(fr)
*
|
2018-11-20 |
2021-09-29 |
H Lee Moffitt Cancer Center & Res Institute Inc |
Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
|
|
US12466818B2
(en)
|
2018-11-20 |
2025-11-11 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
US20220143049A1
(en)
|
2019-03-21 |
2022-05-12 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|